Kornimate/medical-research-clean huggingface dataset:
physical activity intervention for lung cancer survivors

Conditions: Lung Cancer; Survivor

Summary: the purpose of this study is to learn how many lung cancer survivors will agree to a physical activity program. we also want to know if lung cancer survivors benefit from this program. this information will help us to develop our services for lung cancer survivors.


Eligibility criteria:
inclusion criteria: * diagnosis and treatment at mskcc of primary nsclc; and/or pulmonary carcinoid; * at least one year post thoracic surgical resection; * have no evidence of nsclc or any other cancer at the time of study enrollment and not receiving any cancer treatment; * currently sedentary or insufficiently active, defined by the american college of sports medicine (acsm) and the centers for disease control and prevention as less than a total of 150 minutes of at least moderate intensity pa per week; * able to complete a six-minute walk test (6mwt); * able to provide informed consent. focus group only: • completed the physical activity program offered through this study (08067); exclusion criteria: * presence of one of the following medical factors at screening: * regular use of an ambulatory aid (cane or walker); * resting oxygen saturation less than 88%; * inability to walk due to severe arthritis or other musculoskeletal problems; * a diagnosis of unstable angina in the previous 6 weeks; * a heart attack, angioplasty or heart surgery in the previous 3 months; * current heart rate \ 120 at rest; current uncontrolled hypertension; * current significant valvular heart disease or decompensated congestive heart failure and * patient reported pain of any origin that would preclude participation in the proposed pa intervention * evidence of significant medical cognitive or psychiatric disturbance sufficient, in the investigator's judgment, to preclude participation in the intervention * self-reporting of greater than 60 minutes of vigorous activity per week or 150 minutes of moderate intensity pa per week. * patient resides at more than two hours travel distance from the center * insufficient english fluency to complete evaluation tools.

Keywords: survivor physical activity ned 08-067
descriptive, post-marketing, surveillance safety study of menactra vaccine

Conditions: Meningitis; Meningococcal Disease

Summary: to further characterize the safety profile of menactra vaccine and to identify any signals of potentially vaccine-related adverse events (aes) not detected during pre-licensure studies.


Eligibility criteria:
inclusion criteria: * receipt of menactra vaccine during the study period. exclusion criteria: * none

Keywords: meningitis meningococcal disease menactra vaccine
validation study of g4 user interface

Conditions: Diabetes Mellitus

Summary: the purpose of this simulated useability study is to demonstrate the user interface and software design mitigate potential safety concerns.

these are the detailed descriptive planned outcomes of this useability study. * to demonstrate that human-interface design mitigations lead to effective, efficient, and safe use. * validate that foreseeable misuse does not lead to a safety hazard or patient injury. * validate the effectiveness and comprehension of critical warnings and alerts, including vibratory, auditory, and textual cues.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of diabetes mellitus
clinical evaluation of an igra test for the diagnosis of active and latent tuberculosis

Conditions: TUBERCULOSIS

Summary: methodology this is a single-center study carried out as part of routine patient care. the aim of the study is to determine the performance of the 2nd generation tb-igra test in the diagnosis of tuberculosis.

it is planned to include 500 patients. an enrolment of 455 subjects will enable us to demonstrate sensitivity-specificity levels of 92% for a 95% confidence interval and a 0.05 degree of precision. to take account of non-analyzable samples or tests, the investigator will include 500 subjects

Eligibility criteria:
inclusion criteria: * individual at least 18 years of age * patient presenting for treatment of tuberculosis disease * having undergone or benefiting from screening for tuberculosis using a medically prescribed reference igra test. * informed patient who has not expressed opposition to participating in the study. french-speaking patient with unambiguous understanding of oral and written instructions. exclusion criteria: persons in a period of exclusion from another study * pregnant, parturient or breast-feeding women; * person deprived of liberty by judicial or administrative decision
share program: sustain

Conditions: Hiv

Summary: the goal of project sustain is to optimize healthy choices to advance an adaptive and scalable intervention designed to improve self-management of alcohol and hiv in young people with hiv (ypwh) while understanding the context for state-wide implementation and sustainment in a hybrid experimental design (hed). sustain utilizes mhealth and telehealth intervention delivery of healthy choices (hc), combined with text messaging between sessions, to increase the likelihood of daily medication adherence (primary outcome), and increase the likelihood of achieving viral suppression and meeting criteria for no risky alcohol use at month 3 (secondary outcome).

primary aim: to test whether, on average, delivering (vs. not delivering) a text messaged prompt focused on medication adherence or stress increases the likelihood of medication adherence by the end of the current day. secondary aim: to test whether offering (vs. not offering) a healthy choices telehealth coaching session at the end of week 2 (day 14) increases the likelihood of achieving viral suppression and meeting criteria for no risky alcohol use at month 3. implementation aim: assess barriers and facilitators to the implementation and sustainment of intervention sequences for state-wide scale up using mixed methods (epis qualitative interviews, youth satisfaction and dose received, fidelity for telehealth, paradata for mhealth, and cost-effectiveness analysis). cross-project moderator aim: explore age, biological sex and gender, ethnicity, other substance use, and mental health as moderators of intervention effects. primary hypothesis to be tested: delivering (vs. not delivering) a text messaged prompt will lead to greater likelihood of medication adherence by the end of the current day. secondary hypothesis to be tested: offering a healthy choices telehealth coaching at the end of week 2 will lead to greater likelihood of achieving viral suppression and meeting criteria for no risky alcohol use at month 3 (post-intervention) compared to not offering a healthy choices telehealth coaching session at the end of week 2.

Eligibility criteria:
inclusion criteria: * be 18 years and 0 months to 29 years and 11 months. * currently reside in florida * history of alcohol use * are not pregnant nor trying to conceive within the study's timeline * are able to read and understand english * have internet access via smartphone, tablet or computer * are willing to provide informed consent. exclusion criteria: * adults unable to consent * prisoners * those using long-acting injectables as hiv medication regimen
localized osteosarcoma in upper egypt: a clinical prediction model

Conditions: Bone Neoplasms

Summary: to assess survival outcome of pediatric patients with localized osteosarcoma of the extremities in upper egypt, identify factors of prognostic significance for survival, and to determine factors predictive of surgical methods employed in these patients, and developing a clinical model for risk prediction.

background osteosarcoma is the most common of all primary malignant bone tumors. accounting for about 2.6% of all pediatric neoplasms, it predominantly occurs in the extremities, with a peak incidence in the second decade of life. in upper egypt, we have a higher proportion of the population in underdeveloped communities with limited access to medical care so the patients usually seek medical advice at advanced stage leading to a higher prevalence of metastatic disease at initial presentation, as well as a greater proportion of larger tumor size that more likely to be associated with potential adverse risk criteria prior to surgery. a previous study from upper egypt showed that a metastatic disease at diagnosis was independently correlated to a dismal outcome. since the effect of many other factors of prognostic significance, such as, gender, age, tumor location and response to chemotherapy may have been mitigated by the large effect of the metastatic disease on the prognosis; so, here, we will analyze the data of 30 patients with non-metastatic osteosarcoma of the extremities, to determine prognostic factors associated with survival, and also to develop a model for a better prediction of factors correlated to that a certain surgical approach was employed in these patients based on their baseline clinical data and the tumor response to chemotherapy. patients \& methods we will carry out a retrospective analysis of data assembled from medical records of 30 pediatric patients with a histologically-verified non-metastatic osteosarcoma of the extremities treated at south egypt cancer institute with a unified chemotherapy protocol between january 2001 and december 2015. these data will be categorized according to demographic data, clinical characteristics, tumor response to chemotherapy, and surgical methods employed in these patients. prognostic factors will be determined using univariable and multivariable methods. a predictive model for surgical outcomes in these patients based on the baseline clinical factors, and their tumor response to chemotherapy will be developed.

Eligibility criteria:
inclusion criteria: * patients whose age less than 19 years. * patients diagnosed with verified osteosarcoma involving the extremities. exclusion criteria: * patients whose age more than 19 years. * non-extremities osteosarcoma .

Keywords: nonmetastatic osteosarcoma pediatric cancer limb salvage prediction model
suggesting score scale for risk of bleeding in bariatric surgery

Conditions: Obesity; Bariatric Surgery Candidate; Complication; Bleeding

Summary: as bleeding is a major risk in bariatric surgeries, we aimed our study to find any predictors to such bleeding within the surgery or 30 days after surgery. the study is a retrospective study collecting patients data, surgeons data, and hospitals data in order to find if any of the factors influencing patients, surgeons or hospitals, has to do with bleeding in these surgeries and if it does impact bleeding in what way. the goal is finding a predictor that it's neutralizing may prevent bleeding in bariatric surgeries.

were collected retrospectively the data of all patients (age 18 and older) that underwent bariatric surgery in assuta hospitals (assuta is a nationwide privet hospitals network), during the years 2013-2016. patients underwent one of three procedures: * laparoscopic sleeve gastrectomy (lsg), * laparoscopic gastrectomy by-pass (lgbp) * laparoscopic adjustable gastric band (lagb) demographic data of patients was collected (age, gender. bmi, habits, smoking, alcohol consumption etc.), as well as medical history, background diseases, family medical history, previous surgeries and procedures, chronic treatments, use of medications etc., we have also collected surgeons and hospital data - in which hospital was the surgery done? surgery technique, surgeon's experience, capacity of surgeon - how many bariatric surgeries are done by the surgeon per months? statistical analyses was done using chi square and fisher's exact test for analyzing specific single variables. when analyzing the possible connection between bmi and bleeding, bmi values were split into three categories 30\ 40. the use of single variable analyses enabled us to focus on a relatively small number of variables in the multivariable analyses. variables that were statistically significant (p\<0.05) were used as independent variables in logistic regression tests.

Eligibility criteria:
inclusion criteria:all patients that underwent bariatric surgery - exclusion criteria: under 18 years old -
a randomized control trial of antibiotic treatment duration for asymptomatic bacteriuria after kidney transplantation

Conditions: Kidney Transplantation; Bacteriuria; Asymptomatic Infections

Summary: the major hypothesis to be tested is that there was no difference in the clinical outcome between 7(short-course) and 14(traditional-course) days of antibiotic treatment for asymptomatic bacteriuria early after kidney transplantation.

introduction: treatment of asymptomatic bacteriuria is a common practice in renal transplant centers leading to prolong exposure of antimicrobial agents with long hospital length of stay. the duration of antibiotics treatment in this condition have never been proposed. objective: to evaluate the proper duration of antibiotic treatment for asymptomatic bacteriuria early (less than 1 month) after kidney transplantation method: this is a prospective, randomized, open labeled, single center study using intention to treat analysis. patients will be identified and after informed consent is obtained, will be randomized to receive 7 or 14 days course of antibiotics.

Eligibility criteria:
inclusion criteria: * first kidney transplantation * asymptomatic bacteriuria exclusion criteria: * refusal to participate in the study * re-transplantation or combined organ transplantation * history of abnormal structure or function in native kidney, ureter and bladder system * kidney transplant recipients with history of recurrent urinary tract infection or incomplete course of urinary tract infection treatment before transplantation * hemodynamic unstable * urosepsis or other serious infectious complications(eg. symptomatic urinary tract infection/graft pyelonephritis, surgical site infection, infected urinoma/ hospital acquired pneumonia that mandates antibiotic therapy) * surgical complication (eg. anastomosis leakage, collection, ureteric stricture)
a clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastrointestinal tract cancer that cannot be removed with surgery that has spread to other parts of the body

Conditions: Advanced Upper Gastrointestinal Tract Adenocarcinoma

Summary: this randomized phase 3 open-label study will compare the efficacy of the t-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (itim) domain (tigit) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (pd-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti pd-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (gej), and esophageal adenocarcinoma.


Eligibility criteria:
key inclusion criteria: * capable of giving signed informed consent which is in compliance with the requirements and restrictions listed in the informed consent form (icf) and in protocol. * histologically confirmed diagnosis of locally advanced unresectable or metastatic gastric, gej, or esophageal adenocarcinoma. * eastern cooperative oncology group (ecog) performance status of 0-1. * at least one measurable target lesion per response evaluation criteria in solid tumors (recist) v1.1. key exclusion criteria: * underlying medical or psychiatric conditions that, in the investigator's or sponsor's opinion, will make the administration of study-specified therapy hazardous, including but not limited to: * interstitial lung disease, including history of interstitial lung disease or non-infectious pneumonitis. active viral, bacterial, or fungal infections requiring parenteral treatment within 14 days of randomization. * clinically significant cardiovascular disease, such as new york heart association class ii or greater cardiac disease or cerebrovascular accident within 3 months prior to randomization, unstable angina, or new onset angina within 3 months prior to randomization, myocardial infarction within 6 months prior to randomization, or unstable arrhythmia within 3 months prior to randomization. * history of prior solid-organ transplantation, including allogenic bone marrow transplantation. * dementia, psychiatric, or substance abuse disorders that would interfere with satisfying the requirements of the trial. * known human epidermal growth factor receptor 2 (her-2) positive tumor. * known untreated, symptomatic, or actively progressing central nervous system (cns) (brain) metastases. participants with leptomeningeal metastases are excluded from enrollment. * received prior systemic treatment for locally advanced unresectable or metastatic gastric, gej, or esophageal adenocarcinoma. * disease progression within 6 months of completion of neoadjuvant or adjuvant therapy. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: domvanalimab zimberelimab nivolumab advanced upper gastrointestinal tract adenocarcinoma gastroesophageal junction cancer esophageal adenocarcinoma gastric cancer gastric adenocarcinoma
studying innate immune responses in infants with bronchiolitis

Conditions: Bronchiolitis

Summary: this study aims to establish whether impaired innate immune responses are associated with severity of respiratory syncytial virus (rsv) infection.

respiratory syncytial virus (rsv) causes a spectrum of illness in healthy infants, ranging from asymptomatic infection to life threatening bronchiolitis with respiratory failure. the reasons for the differences in clinical presentation remain unknown. interferons are natural antiviral factors and components of the innate immune response, which play a role in limiting viral replication. we postulate that differences in clinical severity of rsv infection may be due to innate immune differences in the production of type i and iii interferons (innate interferons). to test this hypothesis, we will recruit infants with mild, moderate and severe rsv bronchiolitis and compare production of innate interferons in blood and respiratory samples, using quantitative and functional analysis. we will determine whether interferon responses differ across a spectrum of clinical severity, and will relate them to viral load. to establish whether defects in interferon production persist in those infants with severe infection, we will retest them following recovery and measure interferon responses after challenge with live rsv. demonstrating a persisting defect may suggest a genetically determined defect requiring further investigation. identification of the mechanisms of severe disease in patients without known risk-factors could lead to targeted therapy to prevent or treat severe disease.

Eligibility criteria:
inclusion criteria: * bronchiolitis * infant exclusion criteria: * age over 1 year * underlying chronic lung disease, prematurity, congenital heart disease

Keywords: respiratory syncytial virus infant interferon
ultrasound-guided botulinum toxin injection on cricopharyngeal muscle dysfunction

Conditions: Cricopharyngeal Achalasia

Summary: ultrasound-guided injection is a visual, convenient, and radiation-free technique that allows real-time observation of the needle insertion process and drug injection location. the combination with a balloon for fixation further enhances the precision of the injection. in this study, we employed ultrasound-guided injection combined with balloon localization for cricopharyngeal muscle botulinum toxin injection treatment and conducted clinical observations.

the patient's long-term inadequate food intake leads to malnutrition, decreased quality of life, and impacts the prognosis of the disease. currently, both domestically and internationally, treatment options for cricopharyngeal muscle dysfunction include balloon dilation technique, surgical incision, and botulinum toxin injection. passive dilation with a balloon can easily cause mucosal edema and damage. cricopharyngeal myotomy surgery often presents complications such as local infection, excessive bleeding, and local nerve damage. botulinum toxin can alleviate muscle spasms and has been widely used in the treatment of hypertonic disorders \[3\]. common injection localization methods include ultrasound, electromyography, and endoscopy. ultrasound-guided injection is a visual, convenient, and radiation-free technique that allows real-time observation of the needle insertion process and drug injection location. combining it with balloon fixation further enhances the precision of the injection. in this study, we employed ultrasound-guided injection combined with balloon localization for cricopharyngeal muscle botulinum toxin injection treatment and conducted clinical observations.

Eligibility criteria:
inclusion criteria: * videofluoroscopic swallowing study (vfss) confirming incomplete/opening dysfunction of the cricopharyngeal muscle; * no significant improvement in swallowing function after standardized rehabilitation treatment for more than 2 weeks (unchanged or decreased fois); * presence of swallowing initiation, with vfss showing that the upward movement of the hyoid bone during swallowing is greater than half the height of the c3 vertebral body; * stable vital signs, alert consciousness, and cooperation with treatment; exclusion criteria: * patients with severe cognitive impairments, psychiatric disorders, and severe cardiopulmonary diseases; * abnormalities in the pharynx and larynx structures; * patients with malignant tumors; * patients with infections or wounds at the injection site; * patients allergic to botulinum toxin; patients with bleeding tendencies or coagulation disorders.
lidocaine and triamcinolone vs saline trigger point injection for treatment of chronic abdominal wall pain

Conditions: Chronic Abdominal Wall Pain; Abdominal Cutaneous Nerve Entrapment Syndrome

Summary: the purpose of this study is to determine whether the injection of triamcinolone and lidocaine is effective in relieving chronic abdominal wall pain.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic abdominal wall pain * prior ultrasound or cross-sectional imaging of the abdomen to exclude other causes * baseline brief pain inventory score ≥ 5 exclusion criteria: * multiple trigger points * abdominal wall hernia on exam * weight loss * rectal bleeding * recent change in bowel habits * decompensated cirrhosis or recurrent ascites * allergy or contraindication to study medications * known thrombocytopenia with platelet count \< 50,000 * other diagnosis of chronic pain syndromes including fibromyalgia * unable to provide informed consent * pregnancy
progressive muscle relaxation exercises on sleep, fatigue, pain in lymphoma patients

Conditions: Lymphoma Patients

Summary: with regular practice, relaxation has been found to have many benefits such as reducing sensitivity to pain and fatigue, facilitating the transition to sleep, and improving quality of life. therefore, this study was planned to examine the effects of progressive muscle relaxation exercises applied to lymphoma patients on sleep, fatigue, and pain.

a total of 18 sessions of progressive relaxation were performed, 3 days a week for 6 weeks.

Eligibility criteria:
inclusion criteria: * being over 18 years of age * being able to communicate adequately * not having a psychiatric problem * those who are determined by a physician to have no physical obstacle to exercise * individuals who can use technological devices * patients who have had at least 3 cycles exclusion criteria: * those with communication problems * those with psychiatric problems * patients doing any exercise * individuals with phones that do not have a voice recording feature * individuals with phones that do not have a whatsapp feature